TAZ稳定RUNX2驱动左心疾病相关肺动脉高压的肺动脉钙化与肺血管重塑
该研究探讨RUNX2及其经HIPPO通路TAZ调控在左心疾病相关肺动脉高压(PH-LHD)肺动脉平滑肌细胞成骨重编程和血管钙化中的作用。患者及大鼠肺动脉样本显示成骨基因富集、钙化明显,TAZ与RUNX2上调激活并直接互作,TAZ抑制加速RUNX2蛋白降解。大鼠模型中抑制TAZ或RUNX2可减轻肺动脉钙化、远端肺血管重塑及肺动脉高压进展。
要点
- PH-LHD患者和大鼠肺动脉存在明显钙化及成骨基因(含RUNX2)富集。
- TAZ与RUNX2在肺动脉平滑肌细胞中直接互作,TAZ稳定RUNX2蛋白。
- 大鼠模型中抑制TAZ或RUNX2可减轻肺动脉钙化、血管重塑和肺动脉高压。
核心结论
- PH-LHD相关的肺动脉钙化由TAZ依赖性稳定RUNX2驱动,导致肺动脉平滑肌细胞成骨重编程。
- TAZ-RUNX2轴可能是PH-LHD的治疗靶点。
研究设计与样本
- 收集PH-LHD患者及supracoronary aortic banding诱导的PH-LHD大鼠模型的肺动脉样本。
- 进行全基因组RNA测序并评估肺动脉钙化,通过蛋白生化实验解析TAZ与RUNX2的成骨信号。
- 在大鼠模型中测试CADD522抑制RUNX2或verteporfin抑制TAZ的治疗潜力。
主要发现
- 基因本体分析显示PH-LHD患者肺动脉和大鼠肺中成骨及成骨细胞分化基因(包括RUNX2)显著富集。
- 患者和大鼠肺动脉均可见钙化,肺动脉平滑肌细胞中TAZ和RUNX2上调并激活。
- 共免疫沉淀显示肺动脉平滑肌细胞中RUNX2与TAZ直接互作。
- 抑制或敲低TAZ通过加速RUNX2蛋白降解而非减少从头合成来降低RUNX2丰度。
- 大鼠模型中抑制TAZ或RUNX2可减轻肺动脉钙化、远端肺血管重塑及肺动脉高压发展。
临床怎么用
- 在PH-LHD患者中应关注肺动脉钙化及TAZ/RUNX2通路的激活状态。
- TAZ或RUNX2抑制(如verteporfin或CADD522)在动物模型中显示治疗潜力,尚需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Calcification is common in chronic vascular disease, yet its role in pulmonary hypertension due to left heart disease is unknown. Here, we probed for the role of runt-related transcription factor-2 (RUNX2), a master transcription factor in osteogenesis, and its regulation by the HIPPO pathway transcriptional coactivator with PDZ-binding motif (TAZ) in the osteogenic reprogramming of pulmonary artery smooth muscle cells and vascular calcification in patients with pulmonary hypertension due to left heart disease. We similarly examined its role using an established rat model of pulmonary hypertension due to left heart disease induced by supracoronary aortic banding. METHODS: Pulmonary artery samples were collected from patients and rats with pulmonary hypertension due to left heart disease. Genome-wide RNA sequencing was performed, and pulmonary artery calcification assessed. Osteogenic signalling via TAZ and RUNX2 was delineated by protein biochemistry. In vivo, the therapeutic potential of RUNX2 or TAZ inhibition by CADD522 or verteporfin was tested in the rat model. RESULTS: Gene ontology term analysis identified significant enrichment in ossification and osteoblast differentiation genes, including RUNX2, in pulmonary arteries of patients and lungs of rats with pulmonary hypertension due to left heart disease. Pulmonary artery calcification was evident in both patients and rats. Both TAZ and RUNX2 were upregulated and activated in pulmonary artery smooth muscle cells of patients and rats. Co-immunoprecipitation revealed a direct interaction of RUNX2 with TAZ in pulmonary artery smooth muscle cells. TAZ inhibition or knockdown decreased RUNX2 abundance due to accelerated RUNX2 protein degradation rather than reduced de novo synthesis. Inhibition of either TAZ or RUNX2 attenuated pulmonary artery calcification, distal lung vascular remodelling and pulmonary hypertension development in the rat model. CONCLUSION: Pulmonary hypertension due to left heart disease is associated with pulmonary artery calcification that is driven by TAZ-dependent stabilisation of RUNX2, causing osteogenic reprogramming of pulmonary artery smooth muscle cells. The TAZ-RUNX2 axis may present a therapeutic target in pulmonary hypertension due to left heart disease.
引用
- Liu SF, Kucherenko MM, Sang P, et al. RUNX2 is stabilised by TAZ and drives pulmonary artery calcification and lung vascular remodelling in pulmonary hypertension due to left heart disease. Eur Respir J. 2024. PMID: 39542509. doi:10.1183/13993003.00844-2023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。